Holen Sie sich die Stockscreener-App
0.8653
1.54%
0.0131
Handel nachbörslich:
.86
-0.0053
-0.61%
Rani Therapeutics Holdings Inc Aktie (RANI) Neueste Nachrichten
Rani Therapeutics Holdings Inc (RANI) Peer Comparison – Compare with Others - valueresearchonline.com
Rani Therapeutics Holdings Inc (RANI) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Rani (RANI) Earnings Report: EPS Beats Its Estimate in Latest Trading; Trading Response: The Stock Gains 3.41% on the DayGuidance Accuracy Score - vinanet.vn
HC Wainwright Reaffirms "Buy" Rating for Rani Therapeutics (NASDAQ:RANI) - MarketBeat
H.C. Wainwright reiterates Rani Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Rani Therapeutics stock rating at buy - Investing.com
We're Hopeful That Rani Therapeutics Holdings (NASDAQ:RANI) Will Use Its Cash Wisely - webull.com
Chardan Capital Maintains Rani Therapeutics(RANI.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tues - Benzinga
Chardan Capital Initiates Coverage on Rani Therapeutics (NASDAQ:RANI) - MarketBeat
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline - MarketBeat
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Rani Therapeutics (RANI) Edges Lower to $0.80 as Stock Tests Crucial Support ZonePercent Below MA - vinanet.vn
RA Capital details 11,530,414 Rani Therapeutics (RANI) shares under 9.99% cap - Stock Titan
Rani Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Rani Therapeutics Holdings earnings beat by $0.01, revenue topped estimates - Investing.com Canada
8-K: Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Updatemoomoo - Moomoo
Rani Therapeutics (NASDAQ:RANI) Announces Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Rani Therapeutics Q2 Results: EPS beats estimate, sales up 85% - scanx.trade
Rani Therapeutics (RANI) boosts liquidity with $20M raise and Chugai revenue - Stock Titan
Rani Therapeutics reports Q2 2026: $1.7M contract revenue, $8.4M quarterly net loss, $53.4M cash - TradingView
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update - The Manila Times
Rani Therapeutics' Oral RT-114 Tops 150% Bioavailability - Stock Titan
Rani Therapeutics at Canaccord Genuity conference: oral biologics push By Investing.com - Investing.com Canada
RANI: Oral biologics platform shows strong clinical and business momentum, with funding secured into 2027 - TradingView
Rani Therapeutics (RANI) Edges Higher by 2.93% as Shares Approach Key $0.84 ResistanceRevenue Weighted - dars.gov.et
Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Rani Therapeutics Holdings Inc (RANI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RANI Q2'26 Earnings: EPS estimate is (0.05) USD - TradingView
Rani Therapeutics appoints Michelle Gilson to board By Investing.com - Investing.com UK
Rani Therapeutics appoints Michelle Gilson to board - The Globe and Mail
Rani Therapeutics Holdings, Inc. (RANI) awards 247,200 stock options to director - Stock Titan
Rani Therapeutics Holdings, Inc. (RANI) details director option holding - Stock Titan
Rani Therapeutics files Form 3 for director Michelle Gilson - Bitget
Rani Therapeutics Appoints Michelle Gilson to Board of Directors and Names Her Audit Committee Chair - Quiver Quantitative
Rani Therapeutics appoints Michelle Gilson to board and as Audit Committee chair - TradingView
Rani Therapeutics Appoints Michelle Gilson to Board of Directors - Yahoo Finance
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Rani Therapeutics (RANI) Bounces 3.36% to $0.80 as Biotech Stock Holds SupportHigh Yield Stocks - vinanet.vn
Enterprise value to EBITDA forward of Rani Therapeutics Holdings, Inc. – NASDAQ:RANI - tradingview.com
Vanguard Capital Management discloses 5,052,862 Rani Therapeutics (RANI) shares in ownership report - Stock Titan
Oral Biologics Drugs Companies at 22.65% CAGR By 2034 - Fortune Business Insights
Insider Buying: Rani Therapeutics (NASDAQ:RANI) Director Buys $24,840.00 in Stock - MarketBeat
Rani Therapeutics Holdings Inc (RANI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rani Therapeutics Holdings Inc - TradingKey
Rani Therapeutics Holdings Inc (RANI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rani Therapeutics Holdings Inc (RANI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RANI|Rani Therapeutics Holdings Inc|Price:0.810|Chg%:-0.000 - TradingKey
Rani Therapeutics Holdings Inc (RANI) Institutional Confidence - TradingKey
RANI|Rani Therapeutics Holdings Inc|Price:0.847|Chg%:-0.044 - TradingKey
Rani Therapeutics Hldgs Market Sentiment - Benzinga España
RANI|Rani Therapeutics Holdings Inc|Price:0.880| - TradingKey
TradingKey - TradingKey
Rani Therapeutics Holdings Inc (RANI) Cash Flow - TradingKey
Rani Therapeutics Holdings Inc (RANI) Balance Sheet - TradingKey
Rani Therapeutics director Mir A Imran buys $24,839 in stock - Investing.com UK
Form 4 Rani Therapeutics Holdings Inc For: 24 July By Investing.com - Investing.com South Africa
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):